During a press conference, Dr. Ramon Cacabelos, project manager, presented the EB-101 Alzheimer vaccine along with scientific documentation which won the patent to manufacture it in the U.S., which already is negotiating with several multinational agencies to start human clinical trials.
According to the group of Spanish scientists, this is the first Alzheimer’s vaccine able to prevent or reverse the disease manifestations when it has developed, as witnessed with the tests performed in transgenic mice. The results revealed that it could double the life expectancy of patients with Alzheimer’s.
In three or four months the group would be ready to begin clinical trials, which could last up to six to eight years. However, everything depends on the requirements asked by regulatory administration of drugs in the United States, the FDA.